KNR.C -- Breakout on lab validation of COVID-19 detection techUndervalued and overlooked company, in my opinion with the a successful energy efficiency and management line of products with partners like Toyota, Beyond Meat, Brookfield and others. Cash flow positive. $41M mkt cap and 31M float with 45% insider ownership.
Only getting noticed now, after introducing Biocloud virus detection tech that is undergoing testing for real-time detection of COVID-19 in enclosed spaces. Today marked an important first step - lab validation - but there's more to come. Next week, we should expect the news of testing using COVID-19. Lots of hype, certainly, but the fundamental strength of this business is undeniable.
Kontrol’s COVID-19 Technology Prototype Receives Positive Lab Test Results
TORONTO, ON / ACCESSWIRE / August 27, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) ("Kontrol" or "Company") is pleased to announce that the Kontrol BioCloud (or "BioCloud") fully functioning prototype was able to operate in real-time and has received positive lab test results.
"Following lab testing, we have demonstrated that our fully operating prototype, previously announced on August 10, 2020, can detect COVID-19 specific components in air samples under a controlled experiment," says Paul Ghezzi, Chief Executive Officer of Kontrol. "This was a critical milestone that we achieved as it ensures the safety and operating capability of BioCloud and we can now move quickly to testing against the live aerosolized COVID-19 virus. We remain on track with achieving our specific milestones and anticipate live COVID-19 virus testing during the week of August 31."
The controlled testing was conducted by the lab of independent consultant, Dr. David Heinrichs, PhD (Heinrichs Laboratory) - experts in the study of Microbiology and Immunology.
Next Major Milestones
The company has now tested both its proprietary detection chamber as announced on August 19, 2020 and its fully operating prototype. Following testing with the live COVID-19 virus, the Company anticipates that it will be in a position to move to commercialization and production of operating units shortly thereafter.
We continue to fund all BioCloud technology development through internal cash generation and Kontrol will not raise capital to complete testing and pre-commercialization work.
When testing against the live COVID-19 virus the Company seeks to establish the lower detection limits of BioCloud and set final parameters for applications based on room size and number of individuals. These lower detection limits will be part of commercialization specifications.
Commercialization Plans
"We are excited to have a working prototype and a successful result given all the hard work that has gone into the BioCloud," says Gary Saunders VP of Kontrol. "We have sourced all the components required for commercialization and have our supply chain ready to go. The Canadian Government has recently announced $2 billion in federal funding to help schools reopen safely. BioCloud has the potential to be an important tool in creating safe spaces by seeking to detect for the virus and assessing the effectiveness of HVAC system improvements by continuously sampling air in real-time."
The Company anticipates a selling price in the range of $12,000 US per BioCloud unit based on the current supply chain components. The detection chamber is replaceable and represents a potential secondary source of commercialized revenue for Kontrol. Any time the detection chamber comes into contact with the COVID virus it must be disposed of safely and replaced.
New Applications beyond COVID-19
During testing the Company has determined that BioCloud has the capability to detect other airborne viruses in addition to COVID-19. This determination was made based on working with the independent lab consultants and a review of the detection mechanism and specifications. While COVID-19 is the most pressing concern for creating safe spaces, other airborne viruses may have similar characteristics that BioCloud may be able to detect.
About Kontrol BioCloud
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
About Kontrol Energy
Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.
Kontrol Energy is one of Canada's fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean's.
Coronavirus (COVID-19)
Gap fill for HoneywellPossible quick profits on a short position, but the trend is generally upwards. The gap could get filled quickly followed by a return to the upside due to increased sales of surgical masks in the COVID-19 pandemic.
NOG is worth a gambleNOG is a oil and gas company in Minnesota, which is an interest stock that poped up on r/pennystocks and think it might be worth to toss in some money into it. It hasn't perform well at all, yet the reason for this gamble is that the election is coming up and Republicans are pro oil and gas as further green technology is being developed, yet the Democrats want to go full green with their green new deal which could destroy the oil and gas and company.
News
-Elections are coming up this November for the US and Minnesota is a key battleground state. It was Democrat in 2016, yet this year its classified as a battleground state and following 2016 Democrats won with a 1.5% margin. Pretty dam close. Current polls shows that biden was winning by 18, yet now only 2.
Source: projects.fivethirtyeight.com
-ER wasn't great, yet could be due to fact of the covid 19. According to USAtoday as of 8/25, Minnesota is growing in the number of cases.
TA
-Now the upside potential out weights the downside with .6377 being on the table which is a 8.6% drop in price. The upside ranges from 5.7%-50% in the short term from tagets of .742, .8515, and 1.0494.
-This stock is in a long term downtrend, yet high vpvr shows a range of .742-.8515 would be in the realm of possibilities and could be a nice short term trade.
-MACD is rising which is bullish
-RSI is just overbought, yet could be overcome with sideways movements or extreme volatility coming soon.
Final Thoughts
My political view has no affect, yet I would assume a Trump victory would push this stock higher or lower. Whatever party you are a small gamble in a small oil and gas stock from a battle ground state wouldn't be a bad idea. I took a position in this stock today just to see where it goes when we get close to the election/debates/ and after the elctions. If movement starts going up showing massive buys you could suspect the oil sector will being pushing up rapidly. So in the meantime watch the polls, if they are even worth to watch after 2016, to see who Minnesota favors and watch tweets from Trump about Oil and Gas.
Going back to school to LRNKeep an eye on this one -- we like it long right here. Multi-year breakout above $40 last month now holding as support. Deep pullback to the 50dma with a large open interest put level at the 43-strike to act as support as well. Shorts are in covering mode down over -18.03% over the past 2-weeks. Options are moderately priced in the 19th percentile as well.
The Coronavirus Vaccine: Best Trading Tips for GoldGold has not been nearly as affected by the risk-on frenzy as bonds were. In fact, it has been maintaining a range from 1924 to 1964. These are both technical levels. There are some Fibonacci levels in between so watch for support or resistance at these.
The fact that gold is maintaining a $40 range which is quite narrow for this product, suggests a breakout may follow soon. This narrow range is not likely to last, so keep your eye on the upper and lower bounds of the channel for a possible breakout either way. The Kovach OBV is solidly bearish, but this could just be because we are testing the lower bound of the range right now. The level 1925 may provide some support here very soon
LIME - Lime Technologies, ugly hammer reversalCurious about LIME Technologies.
I think this is still a business which has huge potential, but with Covid19 Lime must be suffering as well and there financial numbers won't be great this year.
The hammer candle on the last daily close shows a potential reversal.
Furthermore we have TD Sequential signals in the weekly.
Let's find a longterm entry on LIME, maybe after all the turmoil about elections and covid19 is over.
Happy Trading!
Best Way To Trade Stocks on Coronavirus NewsStocks have solidly broken new highs in the overnight session. It's rare to see such momentum on a Sunday night. We are in new territory, but there is a fibonacci extension for reference at 3417. Another Fibonacci extension suggests resistance at 3429, which is very close. If you have not entered this trade, wait for a pullback before going long. Both Kovach Momentum Indicators are solidly positive, suggesting there is some serious meat to this rally. Just don't FOMO into a top. When the Kovach Chande dips and the Kovach Reversals produces a red triangle, you can consider that as a heads up that a pullback is near.
Moderna Hype Bubble Looks Very BearishFDA's emergency authorization of convalescent plasma doesn't bode well for the valuation of this stock. I'm going to go out on a limb here and say that this is one of, if not the biggest announcements a president has made in the last 50+ years. Our entire economy is shut down and the prospect of a viable vaccine are looking less and less likely. Last I checked the latest news coming out of the Covid 19 vaccine industry is that they may be, at best 60% effective, requiring multiple doses. Now let's not forget that these vaccines will most likely come with significant side effects that may be just as bad or worse than Covid itself. Don't believe me? Think I'm a qwack? Well do your own research and look into the fastest vaccine ever to market, which was for the mumps and it took about 4 years to create. I wouldn't want to be the first guinea pig taking this mystery sauce Fauci / Gates and the rest of the vaccine industry is pushing. Convalescent plasma was also used during the later stages of the 1918 Spanish flu with magnificent success. Great move by Trump.
SP500 (SPX) Crucial Make or Break Moment [Full Explanation]In this analysis I will explain some fundamental concepts about the S&P 500 and how to prepare for a trade in this new week.
The S&P 500 Index is market cap weighted. This method divides the market cap of a company by an index’s total market capitalization to determine the weights. This results in a weightings ranking that matches a market cap ranking.
The stocks of Apple, Amazon, Alphabet, Microsoft and Facebook, the five largest publicly traded companies in America, rose 37 percent in the first seven months this year, while all the other stocks in the S&P 500 fell a combined 6 percent.
This is crazy. This is hardly anywhere close what the SP500 was initially built for. It doesn't give you any proper diversification anymore. It's really basically a SP5 Technology Index now instead of a SP500.
It's important to realize this, as you might think that the stock exchange market has completely recovered from COVID-19. It hasn't.
The major tech companies recovered quickly, as they moved to working from home policies smoothly and had even opportunities rapidly scaling their online business.
The brick and mortar companies didn't. If you want serious gains, consider investing in those companies that didn't recover yet such as Wells Fargo, Bank of America, Hartford Financial Services, or YUM! Brands.
Only a fool will try to bet against the market and hold a short position over a really long time, but I still suggest a temporary short position here. What I mean with that is that this is not a great entry for a long on SPX, especially directly against a zone of incredibly strong resistance.
Make sure to follow the age-old principle of buying low and selling high. The price is not low right now, not enough to justify a long position.
What I suggest is to wait for another retracement, and get a better entry in. You can ride a short position until we get there, or just wait for a retracement and go long when you see fit. I think a value of around $3250 should do for this purpose.
Follow me for consistent high quality updates, with clear explanations and charts.
Please like this post to support me.
- Trading Guru
--------------------------------------------------------------
Disclaimer!
This post does not provide financial advice. It is for educational purposes only!
SRNEFor Sorrento's Fan. GL
Sorrento's COVI-TRACK FDA Registration: www.accessdata.fda.gov
Not a trading call, just sharing my view, Good Luck
COVID/CONFIRMEDI’m going long on Covid we should be at 10,000,000 by December/Early January
Stoploss: 5,000,000
DXY bouncing off multi year trend line As shown on the chart above,
The dollar index, which is the value of the US dollar relative to a basket of foreign currencies, gained strength this week after hitting a multi year trend line support (2011-2020) and a horizontal support around 92.10.
This explains the bearish move for the EUR/USD, which lost around 200 pips in a week.
Not to mention GBP/USD which lost more than 250 pips in a single day.
The bullish DXY move was supported by some fundamentals like rising Covid-19 cases in the European continent and worse than expected PMI data in Germany and France.
Good luck